|
Anavex Life Sciences |AVXL | Profile
Anavex Life Sciences Corp. is a biopharmaceutical company engaged in the discovery and development of new drugs for the treatment of neurological diseases and cancer, utilizing its proprietary drug discovery SIGMACEPTOR™ platform. The Anavex portfolio comprises novel, wholly owned sigma receptor agonists and antagonists. The company’s lead drug candidate for Alzheimer’s Disease (AD), ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose (SAD) clinical trial. The company has also started scale-up manufacturing for ANAVEX 1-41, its second lead compound, targeting depression and AD. With sufficient quantities of ANAVEX 1-41 in hand, the company will be in a position to advance the program and begin preclinical studies on large animals in the near term. Neurological diseases (CNS): Anavex SIGMACEPTOR™-N program involves the discovery and development of original drug candidates, targeting neurological diseases such as Alzheimer’s disease, epilepsy, and depression. The company’s lead drug candidates exhibit high affinity and selectivity to sigma receptors and also synergistic action with other receptors, such as Muscarinic and NMDA, with strong evidence of anti-amnesic, neuroprotective, and anxiolytic properties. Oncology: Anavex SIGMACEPTOR™-C program involves the discovery and development of original drug candidates targeting cancer. The company’s lead drug candidates exhibit high affinity to sigma receptors with strong evidence for selective apoptosis of cancerous cells, without affecting healthy cells, anti-metastatic and low toxicity properties in various types of cancer such as melanoma, prostate and pancreas, and neuropathic pain. In addition, several series of sigma ligands currently at different stages of development, target stroke, diabetes, multiple sclerosis and Parkinson’s disease. The Pipe Line Anavex’s lead drug candidate ANAVEX 2-73 -targeting Alzheimer’s Disease- is in Phase 1 clinical trials. The company has also initiated scale-up manufacturing of ANAVEX 1-41 targeting a range of important CNS disorders, including depression and Alzheimer’s Disease. Three more of its compounds (for malignant melanoma, prostatic cancer and epilepsy) are expected to reach final preclinical stages in the near term. Other early-stage preclinical research (see diagram) involves drug candidates that target diseases like depression, neuropathic pain and various types of cancer. Source: Anavex, OxBridge Research, Daily Stock Deals
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
FastFunds Financial | FFFC | Profile
FastFunds Financial Corporation is a holding company currently operates in the financial services industry segment. The company's wholly-owned subsidiary, NET LIFE Financial Processing, Inc., has acquired the exclusive mortgage servicing rights for NET LIFE Financial Holdings ("NET LIFE") from the holder, a Florida Trust.
NET LIFE is a development stage enterprise that has developed and is offering an innovative new mortgage product that is not based on credit history (no doc) or personal guarantees. It is only secured by the underlying collateral and a life insurance policy on the borrower. Therefore, all that is required to qualify for a mortgage loan is qualifying for a life insurance policy, a down payment that usually amounts to 10% of the purchase price and verification that the borrower has the financial ability to pay the monthly payments. NET LIFE believes this mortgage product will be attractive to a wide spectrum of potential borrowers including:
first time home buyers
Innovative Mortgage Products
FastFunds Financial combined with its partner, NET LIFE, have developed an innovative new mortgage product that is not based on credit history (no doc) or personal guarantees. It is only secured by the underlying collateral and a life insurance policy on the borrower. Therefore, all that is required to qualify for a mortgage loan is qualifying for a life insurance policy, a down payment that usually amounts to 10% of the purchase price and verification that the borrower has the financial ability to pay the monthly payments. NET LIFE believes this mortgage product will be beneficial to a wide spectrum of potential borrowers including individuals and businesses.
NET LIFE LCMO
The Company believes a NET LIFE LCMO (Life Collateralized Mortgage Obligation) could substantially improve America's banking and mortgage crisis. A NET LIFE LCMO is a residential, business or corporate real estate mortgage which is not based on credit history; only on the collateral.
All that is required for which to qualify is: (a.) that you are healthy (b.) that the property maintains and sustains its stated value (c.) that you have the income to pay your mortgage.
All NET LIFE LCMO mortgages are processed, managed and serviced exactly like a conventional mortgage without all of the red-tape qualification. NET LIFE has only reinvented the "vehicle"; not the "wheel" it rides upon.
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
Titan Pharmaceuticals, TTNP, Profile
Titan Pharmaceuticals, TTNP, is a biopharmaceutical Company developing proprietary therapeutics primarily for the treatment of serious medical disorders. Titan’s principal asset is Probuphine®, the first slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”), designed to maintain a stable, round-the-clock blood level of the medicine in patients for up to six months following a single treatment. The outpatient treatment of opioid dependence with daily dosed sublingual buprenorphine formulations represents a $1.3 billion market in the U.S., and a seven day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the U.S. in 2011. This novel implant formulation is inserted subdermally in a patient’s upper arm providing continuous medication, and has the potential to enhance patient compliance to treatment, and limit diversion for illicit use and accidental exposure to the sublingual formulations. The New Drug Application (NDA) was submitted to the FDA in October, 2012 seeking approval for treatment of opioid dependence. In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties. Probuphine is the first product to utilize ProNeura™, a novel, proprietary, long-term drug delivery technology. The ProNeura technology has the potential to be used in developing products for the treatment of other chronic conditions, such as Parkinson’s disease, where maintaining stable, round-the-clock blood levels of a drug can benefit the patient and improve medical outcomes. Finally, Titan is also entitled to royalty revenue of 8-10% of net sales of Fanapt® (iloperidone), an atypical antipsychotic compound being marketed in the U.S. for the treatment of schizophrenia by Novartis Pharma AG (“Novartis”) under a sub-license agreement based on a licensed U.S. patent that expires in October 2016 (does not include a possible six month pediatric extension). Substantially all of this future royalty revenue has been sold to Deerfield Management (“Deerfield”), a healthcare investment fund, in exchange for cash and debt considerations which have been used to advance the development of Probuphine and for general corporate purposes.
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks. Sources: company, OxBridge Research, Daily Stock Deals
Fuse Science, DROP, Profile, Summary
Fuse Science (DROP) is a consumer products company, developed an alternative delivery systems with applications in the sports nutrition and medical fields. Its delivery systems include sublingual and transdermal delivery technologies that enable energy, medicines, vitamins, and minerals to bypass the gastrointestinal tract and enter the blood stream directly.
The company offers EnerJel to address muscle fatigue and soreness, before, during, and after physical activity. It also provides drop products, including PowerFuse, an energy formulation in a concentrated drop, as well as ElectroFuse, an electrolyte formula in a concentrated drop.
Fuse focus provides revolutionary energy and body replenishment products that combine cutting-edge body delivery technology with two proprietary formulas for powering professional athletes and weekend warriors. Utilizing our unique, bonding technology, Fuse Science has a unique electrolyte and energy delivery system for consumers ranging from the serious athletes to working mothers.
A combination of patent pending technology and unique ingredients has resulted in achievement of superior cosemtic, consumable, transdermal and sublinguall delivery of nutraceuticals and pharmaceuticals. This unique delivery system has allowed for increased absorption of encapsulated nutrients across the epidermis and oral mucosa in our transdermal and sublingual formulations.
ENERJEL™
|
BNVI +43%
RDDY +50%
PTEK +64%
WEST +47%
BPAX +107%
ZOOM +24%
HYSR +69%
Small Stocks. Huge Gains.
|


















